Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polistes metricus venom protein is an allergenic extract derived from the venom of the North American paper wasp, *Polistes metricus*. It is primarily utilized in the diagnosis and treatment of Hymenoptera venom hypersensitivity. For diagnostic purposes, it is used in skin prick or intradermal testing to identify IgE-mediated sensitization. Therapeutically, it is administered as venom immunotherapy (VIT), a process involving the subcutaneous injection of increasing doses of the venom to induce immunological tolerance. The mechanism of action involves modulating the immune system's response to allergens, specifically by promoting the production of allergen-specific IgG4 "blocking" antibodies, inducing T-lymphocyte anergy or regulatory T-cell (Treg) activity, and shifting the cytokine profile from a Th2 to a Th1 dominance. This reduces the risk of systemic anaphylactic reactions upon subsequent stings. The extract typically contains major allergens such as Phospholipase A1 (Pol m 1), Hyaluronidase (Pol m 2), and Antigen 5 (Pol m 5).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polistes metricus venom protein.